NCT05230368View on ClinicalTrials.gov

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2026

Conditions
HIV-1-infection, Subtype b
Interventions
DRUG

Decitabine cycle 1

Decitabine administration (5mg/m²) at days 1, 2, 3

DRUG

Romidepsin cycle 1

Romidepsin administration (5mg/m²) at days 4, 11, 18

DRUG

Decitabine cycle 2

Decitabine administration (5mg/m²) at days 35, 36, 37

DRUG

Romidepsin cycle 2

Romidepsin administration (5mg/m²) at days 38, 45, 52

DRUG

Decitabine cycle 3

Decitabine administration (5mg/m²) at days 70, 71, 72

DRUG

Romidepsin cycle 3

Romidepsin administration (5mg/m²) at days 73, 80, 87

DRUG

Decitabine cycle 4

Decitabine administration (5mg/m²) at days 105, 106, 107

DRUG

Romidepsin cycle 4

Romidepsin administration (5mg/m²) at days 108, 115, 122

Trial Locations (1)

1000

RECRUITING

CHU Saint-Pierre, Brussels

All Listed Sponsors
collaborator

INSERM SC10-US19

UNKNOWN

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV